10 Hottest SMID-Cap Stocks So Far In 2025

6. Ventyx Biosciences Inc. (NASDAQ:VTYX)

Sector/Industry: Healthcare/Biotechnology

YTD Total Returns: 338.8%

Market Cap: $686 Million

Number of Hedge Fund Holders: 28

Ventyx Biosciences Inc. (NASDAQ:VTYX) is among the hottest SMID-cap stocks so far in 2025. On November 7, TheFly reported that Canaccord Genuity modestly increased its price target on the company’s stock from $14 to $16 while reiterating a Buy rating following the company’s Q3 results report a day earlier.

Canaccord is now factoring in lower operating expenses in the near term, which has led to the upward revision of the target. The firm trimmed its operating cost estimates based on its analysis of the latest results. Additionally, they expect a streamlined clinical development program with fewer ongoing trials than in the first half of 2025, which should also support lower operating expenses.

As per its Q3 results, Ventyx Biosciences Inc. (NASDAQ:VTYX) ended the quarter with $192.6 million in cash (down from $209 million in Q2 2025), providing operational funding into at least the second half of 2026. Management was able to curtail R&D and General & Administrative (G&A) expenses, which helped it narrow its net loss to $22.8 million, down from $35.2 million in the year-ago period.

The company continued to emphasize the progress it has made with its VTX3232 therapy throughout the year. It now expects Phase 2 topline readouts for VTX2735 in recurrent pericarditis in Q4 2025, which will be keenly watched.

Earlier in October, Ventyx Biosciences Inc. (NASDAQ:VTYX) reported positive Phase 2 Study results for VTX3232, which showed significant reductions in cardiovascular risk factors. Investors responded positively, as the share price skyrocketed 71% the day after the announcement. With that, the stock has rallied 339% year-to-date, as of November 20.

Ventyx Biosciences Inc. (NASDAQ:VTYX) is a clinical-stage biopharmaceutical company that focuses on developing oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases.